Amgen Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.75B | $33.42B | $28.19B | $26.32B | $25.98B | $25.42B | $23.36B | $23.75B |
| Repatha | $3.02B | $2.22B | $1.64B | $1.30B | $1.12B | $887.0M | — | — |
| EVENITY | $2.10B | $1.56B | $1.16B | $787.0M | $530.0M | $350.0M | — | — |
| Prolia | $4.41B | $4.37B | $4.05B | $3.63B | $3.25B | $2.76B | $2.67B | $2.29B |
| TEPEZZA | $1.90B | $1.85B | $448.0M | — | — | — | — | — |
| KRYSTEXXA | $1.34B | $1.19B | $272.0M | — | — | — | — | — |
| UPLIZNA | — | $379.0M | $65.0M | — | — | — | — | — |
| TAVNEOS | — | $283.0M | $134.0M | — | — | — | — | — |
| Ultra-Rare products | — | $758.0M | $164.0M | — | — | — | — | — |
| TEZSPIRE | $1.48B | $972.0M | $567.0M | — | — | — | — | — |
| Otezla | $2.27B | $2.13B | $2.19B | $2.29B | $2.25B | $2.20B | — | — |
| Enbrel | $2.23B | $3.32B | $3.70B | $4.12B | $4.47B | $5.00B | $5.23B | $5.01B |
| AMJEVITA/AMGEVITA | — | $761.0M | $626.0M | — | — | — | — | — |
| BLINCYTO | $1.56B | $1.22B | $861.0M | — | — | — | — | — |
| Vectibix | $1.18B | $1.05B | $984.0M | — | — | — | — | — |
| KYPROLIS | $1.41B | $1.50B | $1.40B | $1.25B | $1.11B | $1.07B | $1.04B | $968.0M |
| LUMAKRAS/LUMYKRAS | — | $350.0M | $280.0M | — | — | — | — | — |
| XGEVA | $2.08B | $2.23B | $2.11B | $2.01B | $2.02B | $1.90B | $1.94B | $1.79B |
| Nplate | $1.52B | $1.46B | $1.48B | $1.31B | $1.03B | $850.0M | — | — |
| IMDELLTRA | — | $115.0M | — | — | — | — | — | — |
| MVASI | — | $727.0M | $800.0M | — | — | — | — | — |
| EPOGEN | — | $125.0M | $226.0M | — | — | — | $867.0M | $1.01B |
| Aranesp | $1.39B | $1.34B | $1.36B | $1.42B | $1.48B | $1.57B | $1.73B | $1.88B |
| Parsabiv | — | $356.0M | $362.0M | — | — | — | — | — |
| Neulasta | — | $431.0M | $848.0M | $1.13B | $1.73B | $2.29B | $3.22B | $4.48B |
| NEUPOGEN | — | — | — | — | — | — | — | — |
| Sensipar/Mimpara | — | — | — | — | — | — | $551.0M | $1.77B |
| Other products | $7.26B | $1.35B | $1.19B | $5.57B | $5.32B | $5.37B | $4.96B | $3.34B |
| Other revenues | $1.60B | $1.40B | $1.28B | $1.52B | $1.68B | $1.18B | $1.16B | $1.21B |
| Cost of Revenue | $12.04B | $12.86B | $8.45B | $6.41B | $6.45B | $6.16B | $4.36B | $4.10B |
| Gross Profit | $24.71B | $20.57B | $19.74B | $19.92B | $19.53B | $19.27B | $19.01B | $19.65B |
| Gross Margin | 67.2% | 61.5% | 70.0% | 75.7% | 75.2% | 75.8% | 81.4% | 82.7% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $7.05B | $7.10B | $6.18B | $5.41B | $5.37B | $5.73B | $5.15B | $5.33B |
| Operating Income | $9.08B | $7.26B | $7.90B | $9.57B | $7.64B | $9.14B | $9.67B | $10.26B |
| Operating Margin | 24.7% | 21.7% | 28.0% | 36.3% | 29.4% | 35.9% | 41.4% | 43.2% |
| Interest Expense | $2.76B | $3.16B | $2.88B | $1.41B | $1.20B | $1.26B | $1.29B | $1.39B |
| Pretax Income | $8.98B | $4.61B | $7.86B | $7.35B | $6.70B | $8.13B | $9.14B | $9.55B |
| Income Tax Expense | $1.27B | $519.0M | $1.14B | $794.0M | $808.0M | $869.0M | $1.30B | $1.15B |
| Net Income | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B | $7.26B | $7.84B | $8.39B |
| Net Margin | 21.0% | 12.2% | 23.8% | 24.9% | 22.7% | 28.6% | 33.6% | 35.3% |
| EPS (Basic) | $14.33 | $7.62 | $12.56 | $12.18 | $10.34 | $12.40 | $12.96 | $12.70 |
| EPS (Diluted) | $14.23 | $7.56 | $12.49 | $12.11 | $10.28 | $12.31 | $12.88 | $12.62 |
| Shares Outstanding (Basic) | 538.0M | 537.0M | 535.0M | 538.0M | 570.0M | 586.0M | 605.0M | 661.0M |
| Shares Outstanding (Diluted) | 542.0M | 541.0M | 538.0M | 541.0M | 573.0M | 590.0M | 609.0M | 665.0M |
| Dividends Per Share | $9.66 | $9.13 | $8.64 | $7.95 | $7.22 | $6.56 | $5.95 | $5.41 |